Nanoparticle Contract Manufacturing Market Size is valued at USD 2.4 Bn in 2023 and is predicted to reach USD 4.3 Bn by the year 2031 at a 7.8% CAGR during the forecast period for 2024-2031.
Nanoparticle contract manufacturing refers to the outsourcing of the production of nanoparticles to specialized companies equipped with the expertise, technology, and facilities to create and manipulate particles at the nanoscale (typically between 1 and 100 nanometers in size). Companies looking to reduce production costs are drawn to these manufacturers because of their large-scale operations and economies of scale. Businesses that want to cut expenses frequently opt for contract manufacturing. One of the main reasons why businesses want to simplify their budgets is cost-effectiveness.
Employing nanotechnology to improve drug delivery and efficacy and minimize adverse effects in nanomedicine is a cutting-edge approach to healthcare that is revolutionizing the pharmaceutical sector. Contract manufacturing for nanoparticles is now necessary to satisfy its complex needs. Handling the intricate formulas and exacting control requirements of nanomedicine is made easier by outsourcing to specialized producers. Furthermore, the need for nanomedicine is rising because of the older population and the rise in chronic disorders. This is because nanoparticles have special properties like improved permeability and prolonged circulation, making them ideal for treating complex chronic ailments.
However, the market growth is hampered by the strict regulatory criteria for the safety and health of the nanoparticle contract manufacturing market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high nanoparticle contract manufacturing because many rules have been created to monitor the quality and efficacy of medications as a result of the pharmaceutical industry's global expansion. In several nations, regulatory agencies have arisen to fulfil the legal needs of drug research. Furthermore, the inflow of R&D capital for creating and commercializing complicated pharmaceuticals via nanoparticle contract manufacturing was constrained by tight rules enacted by multiple governments. Due to the COVID-19 pandemic, which has affected the worldwide market and forced the closure of numerous factories to protect their personnel from contracting the virus, the expansion of the industry may be hindered.
Competitive Landscape
Some Major Key Players In The Nanoparticle Contract Manufacturing Market:
- AstraZeneca
- Evonik Industries AG
- Ascendia Pharmaceuticals
- Axolabs (LGC Limited)
- AVANSA Technology & Services
- Ardena Holding NV.
- Cytodiagnostics, Inc.
- American Elements
- Encapsula NanoSciences LLC
- Fortis Life Sciences
- Hongwu International Group Ltd.
- MyBiotech
- Nanochemazone
- CordenPharma
- LSNE Contract Manufacturing
- Polymun
- TeachNanoIndia
- BIOVECTRA
- Precision NanoSystems
- Emergent BioSolutions
- Other Prominent Players
Market Segmentation:
The nanoparticle contract manufacturing market is segmented based on the type of nanoparticles, manufacturing scale, application, and end-user. Based on the type of nanoparticles, the market is segmented into metal nanoparticles, lipid nanoparticles, and others. By manufacturing scale, the market is segmented into commercial, clinical, and pre-clinical. By application, the market is segmented into therapeutics, diagnostics, and vaccines. By end-user, the market is segmented into pharmaceutical companies and biotechnology companies.
Based On The Type Of Nanoparticles, The Metal Nanoparticles Segment Is Accounted As A Major Contributor To The Nanoparticle Contract Manufacturing Market
The metal nanoparticle contract manufacturing market is expected to hold a major global market share. Metal nanoparticles are the most common type in the nanoparticle contract manufacturing industry because of their unique characteristics and wide range of uses. They are versatile enough to be used in various industries, the most notable being healthcare.
Pharmaceutical Companies Segment Witnessed A Rapid Growth.
Pharmaceutical companies expected to lead the market due to increased knowledge about pharmaceutical drug delivery systems. The ever-changing life science industry is driving the market. New advancements are raising awareness about pharmaceutical drug delivery systems, especially in countries like the US, Germany, the UK, China, and India.
In The Region, The North American Nanoparticle Contract Manufacturing Market Holds A Significant Revenue Share.
The North American nanoparticle contract manufacturing market is expected to record the maximum market revenue share in the near future. It can be attributed to because of the rapid development of technology in underdeveloped regions. In addition, Europe is predicted to grow rapidly in the global nanoparticle contract manufacturing market because of significant progress in materials science and nanotechnology. Innovation brought about by these breakthroughs has spurred nanoparticle manufacturing processes.
Recent Developments:
- In Feb 2024, CordenPharma International has introduced new Lipid NanoParticle (LNP) Starter Kits to enhance the formulation of mRNA in the development of mRNA-based treatments, including mRNA vaccines and gene therapies. The given starter kits equip researchers and developers with the necessary components to establish and enhance their own lipid nanoparticle (LNP) systems for delivering mRNA.
- In July 2023, Ardena, a prominent contract development producer of nanomedicines, has formed a strategic commercial relationship with RiboPro, experts in mRNA and LNP technology. The objective of this collaboration is to improve the worldwide availability of RNA-based healthcare therapies and address a substantial deficiency of skilled personnel within the industry.
Nanoparticle Contract Manufacturing Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.4 Bn |
|
Revenue Forecast In 2031 |
USD 4.3 Bn |
|
Growth Rate CAGR |
CAGR of 7.8% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type Of Nanoparticles, Manufacturing Scale, Application, And End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
AstraZeneca, Inc., Evonik Industries AG, Ascendia Pharmaceuticals, Axolabs (LGC Limited), AVANSA Technology & Services, Ardena Holding NV, Cytodiagnostics, Inc., American Elements, Encapsula NanoSciences LLC, Fortis Life Sciences, Hongwu International Group Ltd., MyBiotech, and Nanochemazone, CordenPharma, LSNE Contract Manufacturing, Polymun, TeachNanoIndia, BIOVECTRA, Precision NanoSystems, Emergent BioSolutions and Other Prominent Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
